Boston Scientific’s coronary IVL catheter hits primary endpoints in trial
Boston Scientific plans to use the IDE trials results to support a regulatory filing of its Seismiq 4CE Coronary catheter…
Featured s
Enabling steerability at the microscale: the significance of nitinol
Nitinol’s superelasticity and shape memory enable ultra-flexible, steerable micro-instruments that are transforming GI, vascular and neurovascular procedures, says Alleima.
All Articles
Boston Scientific’s coronary IVL catheter hits primary endpoints in trial
Boston Scientific plans to use the IDE trials results to support a regulatory filing of its Seismiq 4CE Coronary catheter…
Enabling steerability at the microscale: the significance of nitinol
Nitinol’s superelasticity and shape memory enable ultra-flexible, steerable micro-instruments that are transforming GI, vascular and neurovascular procedures, says Alleima.
Philips introduces SmartIQ AI software for coronary imaging advancement
SmartIQ is specifically designed to address the trade-off between image quality and radiation dose levels in coronary imaging procedures.
Hospital at home: the new model of modern care
Professor Rachid El Fatimy, dean of the Faculty of Medical Sciences and hospital general director at University Mohammed VI Polytechnic…
EmStop begins CAPTURE-2 trial of embolic protection system
The trial will examine the EmStop system’s safety and performance as a cerebral embolic protection device.
Boston Scientific invests $1.5bn for equity stake in MiRus
Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones.
Artivion strengthens aortic arch portfolio with $135m Endospan acquisition
As per a 2019 deal, Artivion secured the rights to purchase Endospan upon the latter’s US approval of Nexus, a…
Podcast: MHRA CEO Lawrence Tallon on the future of medical device regulation in the UK
Lawrence Tallon, CEO of the MHRA, discusses the agency's initiatives to advance the UK's regulatory protocols for medical devices.
Embecta acquires Owen Mumford for $172.6m
The transaction supports Embecta’s plan to diversify by supplying drug delivery solutions to pharmaceutical partners.
Valar Labs hits US first with breakthrough designation for AI bladder cancer test
Valar Labs’ Vesta Bladder Risk Stratify Dx generates risk assessments for bladder cancer patients by analysing stained pathology slides.
